These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 36292649)
1. Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment. Raphael A; Salmon-Divon M; Epstein J; Zahavi T; Sonnenblick A; Shachar SS Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292649 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer. Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934 [TBL] [Abstract][Full Text] [Related]
3. Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program. Bello Roufai D; Gonçalves A; De La Motte Rouge T; Akla S; Blonz C; Grenier J; Gligorov J; Saghatchian M; Bailleux C; Simon H; Desmoulins I; Tharin Z; Renaud E; Bertho M; Benderra MA; Delaloge S; Robert L; Cottu P; Pierga JY; Loirat D; Bertucci A; Renouf B; Bidard FC; Lerebours F Oncogene; 2023 Jun; 42(23):1951-1956. PubMed ID: 36611120 [TBL] [Abstract][Full Text] [Related]
4. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR Sammons S; Shastry M; Dent S; Anders C; Hamilton E Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379 [TBL] [Abstract][Full Text] [Related]
5. A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). Mayer IA; Prat A; Egle D; Blau S; Fidalgo JAP; Gnant M; Fasching PA; Colleoni M; Wolff AC; Winer EP; Singer CF; Hurvitz S; Estévez LG; van Dam PA; Kümmel S; Mundhenke C; Holmes F; Babbar N; Charbonnier L; Diaz-Padilla I; Vogl FD; Sellami D; Arteaga CL Clin Cancer Res; 2019 May; 25(10):2975-2987. PubMed ID: 30723140 [TBL] [Abstract][Full Text] [Related]
6. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. André F; Ciruelos EM; Juric D; Loibl S; Campone M; Mayer IA; Rubovszky G; Yamashita T; Kaufman B; Lu YS; Inoue K; Pápai Z; Takahashi M; Ghaznawi F; Mills D; Kaper M; Miller M; Conte PF; Iwata H; Rugo HS Ann Oncol; 2021 Feb; 32(2):208-217. PubMed ID: 33246021 [TBL] [Abstract][Full Text] [Related]
7. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications. Vernieri C; Corti F; Nichetti F; Ligorio F; Manglaviti S; Zattarin E; Rea CG; Capri G; Bianchi GV; de Braud F Breast Cancer Res; 2020 Apr; 22(1):33. PubMed ID: 32252811 [TBL] [Abstract][Full Text] [Related]
8. Alpelisib for André F; Ciruelos E; Rubovszky G; Campone M; Loibl S; Rugo HS; Iwata H; Conte P; Mayer IA; Kaufman B; Yamashita T; Lu YS; Inoue K; Takahashi M; Pápai Z; Longin AS; Mills D; Wilke C; Hirawat S; Juric D; N Engl J Med; 2019 May; 380(20):1929-1940. PubMed ID: 31091374 [TBL] [Abstract][Full Text] [Related]
9. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Rugo HS; Lerebours F; Ciruelos E; Drullinsky P; Ruiz-Borrego M; Neven P; Park YH; Prat A; Bachelot T; Juric D; Turner N; Sophos N; Zarate JP; Arce C; Shen YM; Turner S; Kanakamedala H; Hsu WC; Chia S Lancet Oncol; 2021 Apr; 22(4):489-498. PubMed ID: 33794206 [TBL] [Abstract][Full Text] [Related]
10. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial. Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS JAMA Oncol; 2019 Feb; 5(2):e184475. PubMed ID: 30543347 [TBL] [Abstract][Full Text] [Related]
11. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer. Mayer IA; Abramson VG; Formisano L; Balko JM; Estrada MV; Sanders ME; Juric D; Solit D; Berger MF; Won HH; Li Y; Cantley LC; Winer E; Arteaga CL Clin Cancer Res; 2017 Jan; 23(1):26-34. PubMed ID: 27126994 [TBL] [Abstract][Full Text] [Related]
12. Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR Bardia A; Hurvitz SA; DeMichele A; Clark AS; Zelnak A; Yardley DA; Karuturi M; Sanft T; Blau S; Hart L; Ma C; Rugo HS; Purkayastha D; Moulder S Clin Cancer Res; 2021 Aug; 27(15):4177-4185. PubMed ID: 33722897 [TBL] [Abstract][Full Text] [Related]
13. Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2- Advanced Breast Cancer in the USA? Wu W; Lin H; Cai J; Sun H; Liu J; Hu C; Wei X Clin Drug Investig; 2023 Dec; 43(12):939-948. PubMed ID: 37975961 [TBL] [Abstract][Full Text] [Related]
14. Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. Yi Z; Ma F; Liu B; Guan X; Li L; Li C; Qian H; Xu B BMC Cancer; 2019 May; 19(1):442. PubMed ID: 31088410 [TBL] [Abstract][Full Text] [Related]
15. A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ Pérez-Fidalgo JA; Criscitiello C; Carrasco E; Regan MM; Di Leo A; Ribi K; Adam V; Bedard PL Future Oncol; 2022 Jun; 18(19):2339-2349. PubMed ID: 35465733 [TBL] [Abstract][Full Text] [Related]
16. Patient-Reported Outcomes in Patients With Ciruelos EM; Rugo HS; Mayer IA; Levy C; Forget F; Delgado Mingorance JI; Safra T; Masuda N; Park YH; Juric D; Conte P; Campone M; Loibl S; Iwata H; Zhou X; Park J; Ridolfi A; Lorenzo I; André F J Clin Oncol; 2021 Jun; 39(18):2005-2015. PubMed ID: 33780274 [TBL] [Abstract][Full Text] [Related]
17. A Cohort Study of the Antitumor Efficacy and Toxicity Profile of Alpelisib for Metastatic or Locally Advanced HR+, HER2- Breast Cancer: A Single-Institution Experience. Sarfraz H; Bari S; Whiting J; Sur M; Mo Q; Armitage M; Costa RLB Oncology; 2024; 102(5):414-424. PubMed ID: 38011835 [TBL] [Abstract][Full Text] [Related]
18. FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer. Narayan P; Prowell TM; Gao JJ; Fernandes LL; Li E; Jiang X; Qiu J; Fan J; Song P; Yu J; Zhang X; King-Kallimanis BL; Chen W; Ricks TK; Gong Y; Wang X; Windsor K; Rhieu SY; Geiser G; Banerjee A; Chen X; Reyes Turcu F; Chatterjee DK; Pathak A; Seidman J; Ghosh S; Philip R; Goldberg KB; Kluetz PG; Tang S; Amiri-Kordestani L; Theoret MR; Pazdur R; Beaver JA Clin Cancer Res; 2021 Apr; 27(7):1842-1849. PubMed ID: 33168657 [TBL] [Abstract][Full Text] [Related]
19. Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2. Damodaran S; O'Sullivan CC; Elkhanany A; Anderson IC; Barve M; Blau S; Cherian MA; Peguero JA; Goetz MP; Plourde PV; Portman DJ; Moore HCF Ann Oncol; 2023 Dec; 34(12):1131-1140. PubMed ID: 38072513 [TBL] [Abstract][Full Text] [Related]
20. Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors. Fuentes-Antrás J; Martínez-Rodríguez A; Guevara-Hoyer K; López-Cade I; Lorca V; Pascual A; de Luna A; Ramírez-Ruda C; Swindell J; Flores P; Lluch A; Cescon DW; Pérez-Segura P; Ocaña A; Jones F; Moreno F; García-Barberán V; García-Sáenz JÁ Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511178 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]